Will the FDA approve anito-cel for multiple myeloma at its December 23 review?

Question

This market resolves YES if the US FDA grants marketing approval to anitocabtagene autoleucel, also called anito-cel, for treating relapsed or refractory multiple myeloma in the application cycle whose target action date is December 23, 2026. The approved active cellular product must be anito-cel, not another BCMA-directed therapy owned by Gilead or another company.

Approval for a restricted number of prior treatment lines or a narrower adult patient group qualifies as long as the authorised in

Problyx · Accepted Answer

Yes — the community forecast puts this at 83%.

Problyx · Answer

No — the community forecast puts this at 17%.